Recursion Pharmaceuticals (RXRX) EBT Margin (2020 - 2026)
Recursion Pharmaceuticals' (RXRX) quarterly EBT Margin came in at 1886.71% in Q1 2026, down 51238.0% YoY from N/an in Q1 2025, and down 520.25% on a QoQ basis from 304.19% in Q4 2025.
Recursion Pharmaceuticals (RXRX) EBT Margin (2020 - 2026) Analysis & Trends
Recursion Pharmaceuticals (RXRX) has 7 years of EBT Margin data on file, last reported at 1886.71% in Q1 2026.
- Quarterly EBT Margin fell 51238.0% year-over-year to 1886.71% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 849.83% (up 11234.0% YoY) and the FY2025 annual result came in at 863.53%, down 7360.0% from the prior year.
- EBT Margin retreated to 1886.71% in Q1 2026, from 304.19% in the prior quarter.
- In the past five years, EBT Margin ranged from a high of 304.19% in Q4 2025 to a low of 3935.31% in Q4 2024.
- A 5-year average of 1125.88% and a median of 862.72% in 2022 frame the typical range for EBT Margin.
- Annual changes were most pronounced in 2024 — EBT Margin plunged 304413 bps — and 2025, when it soared 363112 bps.
- Tracing RXRX's EBT Margin over 5 years: stood at 497.59% in 2022, then tumbled by 79 bps to 891.18% in 2023, then plunged by 342 bps to 3935.31% in 2024, then soared by 92 bps to 304.19% in 2025, then plunged by 520 bps to 1886.71% in 2026.
- The last three EBT Margin figures came in at 1886.71% (Q1 2026), 304.19% (Q4 2025), and 3135.27% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 41.75% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 35.61% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 34.77% |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 18.33% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -94.22% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 12.09% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 13.77% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -2.67% |
| 10 | Recursion Pharmaceuticals | 1.69 Bn | 1.14 Bn | -3.82 Mn | -1,708.03% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -1,708.03% |
| Mar 31, 2026 | -1,886.71% |
| Dec 31, 2025 | -304.19% |
| Sep 30, 2025 | -3,135.27% |
| Jun 30, 2025 | -894.23% |
| Mar 31, 2025 | -1,374.33% |
| Dec 31, 2024 | -3,935.31% |
| Sep 30, 2024 | -366.82% |
| Jun 30, 2024 | -680.19% |
| Mar 31, 2024 | -668.06% |
| Dec 31, 2023 | -891.18% |
| Sep 30, 2023 | -883.10% |
| Jun 30, 2023 | -696.43% |
| Mar 31, 2023 | -538.38% |
| Dec 31, 2022 | -497.59% |
| Sep 30, 2022 | -475.58% |
| Jun 30, 2022 | -862.72% |
| Mar 31, 2022 | -1,049.97% |
| Dec 31, 2021 | -2,565.14% |
| Sep 30, 2021 | -1,839.86% |